Magazine Article | May 2, 2022

Is Biopharma Poised For Bigger Deals In 2022?

Source: Life Science Leader

By Benet O'Reilly

After total deal value in the biopharma industry dipped to $108 billion in 2021 — its second-lowest level in eight years — it's natural to speculate whether that trend will continue in 2022. Will we see a resumption of transformative dealmaking? Or will we continue to see a high level of lower-value deals featuring bolt-on transactions, partnerships, and alliances?

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: